Gadobutrol Monohydrate
[CAS# 198637-52-4]

Identification

• Classification: Pharmaceutical intermediate >> Heterocyclic compound intermediate >> Pyrimidine compound >> Alcohol
• Name: Gadobutrol Monohydrate
• Synonyms: 2-[4,10-bis(carboxylatomethyl)-7-(1,3,4-trihydroxybutan-2-yl)-1,4,7,10-tetrazacyclododec-1-yl]acetate;gadolinium(3+) hydrate
• Molecular Formula: C₁₈H₃₃GdN₄O₁₀
• Molecular Weight: 622.73
• CAS Registry Number: 198637-52-4
• SMILES: C1CN(CCN(CCN(CCN1CC(=O)[O-])CC(=O)[O-])C(CO)C(CO)O)CC(=O)[O-].O.[Gd+3]

Safety Data

• Hazard Symbols: GHS07 Warning
• Hazard Statements: H315-H319-H335
• Precautionary Statements: P261-P264-P271-P280-P302+P352-P304+P340-P305+P351+P338-P312-P362-P403+P233-P501

Discovory and Applicatios

Gadobutrol Monohydrate is a chemical compound that is primarily used as a contrast agent in magnetic resonance imaging (MRI). It is a water-soluble, gadolinium-based compound that enhances the visibility of blood vessels, tissues, and organs during MRI scans, making it a critical component in diagnostic imaging. Gadobutrol is a macrocyclic chelate compound in which the gadolinium ion is tightly bound, which minimizes the risk of releasing free gadolinium, a potentially toxic substance.

The discovery of Gadobutrol Monohydrate is rooted in the development of gadolinium-based contrast agents, which have been designed to provide clear, enhanced imaging for better diagnostic accuracy in clinical settings. Gadolinium, a rare earth element, was identified in the mid-20th century as a potential candidate for MRI contrast due to its paramagnetic properties, which influence the magnetic field and provide better contrast between different tissues. The challenge was to ensure that gadolinium could be safely incorporated into a compound that would not release toxic amounts of free gadolinium into the body. The development of gadolinium chelates, including Gadobutrol, addressed this issue by using a chelating agent to firmly bind the gadolinium ion.

Gadobutrol itself was introduced as a safer alternative in MRI contrast agents. It is a high-relaxivity contrast agent, meaning it provides enhanced image quality even at lower doses. This characteristic is important in reducing the overall amount of gadolinium required for effective imaging. The introduction of Gadobutrol Monohydrate into clinical use was a significant advancement in MRI technology, providing improved safety profiles and enhanced imaging capabilities. The monohydrate form is stable and ensures proper formulation, which is important for the consistent and reliable use of the agent in clinical applications.

In clinical applications, Gadobutrol Monohydrate is widely used in diagnostic imaging for a range of medical conditions. Its primary use is in MRI scans, particularly for patients who require detailed imaging of the brain, spine, heart, and blood vessels. Gadobutrol Monohydrate’s ability to enhance the contrast of MRI images makes it an essential tool for detecting abnormalities such as tumors, vascular diseases, and neurological disorders. It is also used in the evaluation of various organ systems, providing clinicians with the ability to assess structural and functional abnormalities with greater precision.

Apart from its use in MRI, Gadobutrol Monohydrate is involved in clinical trials for further exploring its potential applications in other diagnostic fields. The compound is well-regarded for its low toxicity, high stability, and excellent contrast properties, making it a preferred agent in many medical imaging procedures. Its application has contributed significantly to the field of medical imaging by improving the diagnostic capabilities of MRI, allowing healthcare professionals to make more accurate and timely diagnoses.

In summary, Gadobutrol Monohydrate has established itself as a crucial component in MRI technology. Its development has allowed for safer, more effective contrast imaging, aiding in the diagnosis of various medical conditions. The compound's discovery and applications continue to support advancements in medical imaging, benefiting both healthcare providers and patients.